Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 135 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019

A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017

Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007

Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006

Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
NEJM 352: 777-785, 828, Mayer, S.A., et al, 2005

Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005

Treatment-Induced Leukoencephalopathy in Primary CNS Lymphoma,A Clinical and Autopsy Study
Neurol 62:451-456, Lai,R.,et al, 2004

The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004

Intoxication with Riluzole in Huntington's Diease
Neurol 57:1141-1143, Bodner,Th.,et al, 2001

Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000

Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999

Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter 40:59-60, , 1998

HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998

New Antiepileptic Drugs
Arch Neurol 55:1181-1183, Bourgeois,B.F.D., 1998

Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998

Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998

New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996

The Use of Parenteral Antiepileptic Drugs & The Role of Fosphenytoin
(Suppl Editor) , Neurol 46:S1-S2896., Wilder,B.J., 1996

New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996

Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994

Next-Day Memory Impairment with Triazolam Use
Lancet 337:827-831, Bixler,E.O.,et al, 1991

Cognitive Impairment Associated with Beta-Blockade in the Elderly
Postgrad Med J 66:1050-1052, Rogers,T.K.&Bowman,C.E., 1990

Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988

Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022

Maternal Use of antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children
JAMA 318:1700-1701, Bromley, R.L.,et al, 2017

Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015

Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014

ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014

Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014

Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through Breastfeeding
JAMA Neurol 70:1367-1374, Veiby, G.,et al, 2013

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010



Showing articles 0 to 50 of 135 Next >>